{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:54:15Z","timestamp":1792450455337,"version":"4.5.0"},"reference-count":171,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":159,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized in cancer patients and survivors, yet it remains underdiagnosed and its epidemiology largely unknown. This statement underscores the imperative need to include HFpEF in the cardiotoxicities identified during or after anticancer treatments. It also highlights the prognostic value of pre-existing HFpEF for periprocedural and cardiotoxicity risk and it discusses the challenges in the diagnosis and treatment of HFpEF in cancer patients. It also explores the aetiologic role of anticancer therapies (chemotherapy, targeted and hormonal therapies and radiotherapy) in the pathogenesis of HFpEF. Special emphasis is given on the importance of considering HFpEF from cancer diagnosis throughout treatment and survivorship and provides useful insights for cardiologists and oncologists in the monitoring and management of these patients. Finally, it highlights the key gaps in current knowledge that require further investigation through well-designed research trials to enhance our understanding and improve clinical outcomes.<\/jats:p>","DOI":"10.1002\/ejhf.70005","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T17:00:27Z","timestamp":1757696427000},"page":"2152-2167","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Heart Failure with Preserved Ejection Fraction in Cancer Patients and Survivors. A Scientific Statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9533-6951","authenticated-orcid":false,"given":"Kalliopi","family":"Keramida","sequence":"first","affiliation":[{"name":"Cardiology Department, General Anti-Cancer, Oncological Hospital, Agios Savvas , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lopez-Fernandez","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Unit, Cardiology Department, IdiPAZ Research Institute, La Paz University Hospital , Madrid ,","place":["Spain"]},{"name":"Cardiology Department, Quironsalud Madrid University Hospital , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus S.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit\u00e9, Campus Benjamin Franklin , Berlin ,","place":["Germany"]},{"name":"Berlin Institute of Health , Berlin ,","place":["Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research), partner site Berlin , Berlin ,","place":["Germany"]},{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, British Heart Foundation Glasgow Cardiovascular Research Centre , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ameri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genova , Genoa ,","place":["Italy"]},{"name":"IRCCS Ospedale Policlinico San Martino , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Cardiovascular Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George's, University of London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Bergler-Klein","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Clinic of Internal Medicine II, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Cardiology, University of Texas MD Anderson Cancer Center , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Iba\u00f1ez","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) , Madrid ,","place":["Spain"]},{"name":"Cardiology Department, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital , Madrid ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore , Singapore ,","place":["Singapore"]},{"name":"Duke-National University of Singapore Medical School , Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninian N.","family":"Lang","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Service, Royal Brompton Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Mirabel","sequence":"additional","affiliation":[{"name":"Cardiology Department, General Anti-Cancer, Oncological Hospital, Agios Savvas , Athens ,","place":["Greece"]},{"name":"INSERM , Paris ,","place":["France"]},{"name":"Institut Mutualiste Montsouris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Moura","sequence":"additional","affiliation":[{"name":"Armed Forces Hospital, Porto Portugal; Faculty of Medicine of the University of Porto , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Paulus","sequence":"additional","affiliation":[{"name":"Department of Physiology and Amsterdam Cardiovascular Sciences, Amsterdam, Amsterdam University Medical Center ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Rakisheva","sequence":"additional","affiliation":[{"name":"City Cardiology Center , Almaty ,","place":["Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education at S\u00f6dersjukhuset, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"University of Milano-Bicocca , Milan ,","place":["Italy"]},{"name":"Cardiovascular Department, ASST Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences (DISMET), Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-0332","authenticated-orcid":false,"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"2026080802425533100_ejhf70005-bib-0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026080802425533100_ejhf70005-bib-0002","first-page":"1810","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0003","first-page":"1188","article-title":"Long-term risk of heart failure in adult cancer survivors: A systematic review and meta-analysis","volume":"110","author":"Wong","year":"2024","journal-title":"Heart"},{"key":"2026080802425533100_ejhf70005-bib-0004","article-title":"Does HFpEF represent a risk factor and a marker of cardiotoxicity in patients undergoing cancer treatment?","volume":"45","author":"Von Kemp","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0005","first-page":"53","article-title":"Lifestyle and cardiovascular risk factors associated with heart failure subtypes in postmenopausal breast cancer survivors","volume":"4","author":"Reding","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026080802425533100_ejhf70005-bib-0006","first-page":"1388","article-title":"Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer","volume":"135","author":"Saiki","year":"2017","journal-title":"Circulation"},{"key":"2026080802425533100_ejhf70005-bib-0007","first-page":"1946","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026080802425533100_ejhf70005-bib-0008","first-page":"280","article-title":"Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0009","first-page":"1720","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: The CARDIOTOX registry","volume":"41","author":"L\u00f3pez-Send\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0010","first-page":"669","article-title":"Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer","volume":"193","author":"Kwan","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2026080802425533100_ejhf70005-bib-0011","first-page":"3889","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0012","first-page":"2511","article-title":"Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: Results from the St. Jude lifetime cohort study","volume":"65","author":"Armstrong","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0013","first-page":"377","article-title":"Prevalence of diastolic dysfunction in adult survivors of childhood cancer: A report from SJLIFE cohort","volume":"5","author":"Palmer","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026080802425533100_ejhf70005-bib-0014","first-page":"33","article-title":"Aging and HFpEF: Are we running out of time?","volume":"168","author":"Withaar","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0015","volume-title":"Age and cancer risk","author":"National Cancer Institute"},{"key":"2026080802425533100_ejhf70005-bib-0016","first-page":"488","article-title":"Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials","volume":"25","author":"Dobbin","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0017","first-page":"497","article-title":"Gender-specific risks for incident cancer in patients with different heart failure phenotypes","volume":"12","author":"Chen","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0018","first-page":"1025","article-title":"Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: A study using the Swedish Heart Failure Registry","volume":"108","author":"Ergatoudes","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0019","first-page":"1515","article-title":"Cancer and heart disease: Associations and relations","volume":"21","author":"Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0020","first-page":"1945","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0021","first-page":"4","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0022","first-page":"188","article-title":"Heart failure with preserved ejection fraction as an independent risk factor of mortality after cardiothoracic surgery","volume":"156","author":"Nguyen","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026080802425533100_ejhf70005-bib-0023","first-page":"580","article-title":"Comparison of 5-year outcomes after coronary artery bypass grafting in heart failure patients with versus without preserved left ventricular ejection fraction (from the CREDO-Kyoto CABG Registry Cohort-2)","volume":"116","author":"Marui","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0024","first-page":"e131","article-title":"Effect of heart failure with preserved ejection fraction on perioperative outcomes in patients undergoing hip fracture surgery","volume":"28","author":"Bohsali","year":"2020","journal-title":"J Am Acad Orthop Surg"},{"key":"2026080802425533100_ejhf70005-bib-0025","first-page":"14","article-title":"Clinical agreement in the American Society of Anesthesiologists physical status classification","volume":"7","author":"Knuf","year":"2018","journal-title":"Perioper Med (Lond)"},{"key":"2026080802425533100_ejhf70005-bib-0026","first-page":"3826","article-title":"2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery","volume":"43","author":"Halvorsen","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0027","first-page":"280","article-title":"Outcomes of patients with stable heart failure undergoing elective noncardiac surgery","volume":"83","author":"Xu-Cai","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2026080802425533100_ejhf70005-bib-0028","first-page":"45","article-title":"Perioperative outcome and long-term mortality for heart failure patients undergoing intermediate- and high-risk noncardiac surgery: Impact of left ventricular ejection fraction","volume":"16","author":"Healy","year":"2010","journal-title":"Congest Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0029","first-page":"66","article-title":"Heart failure and the risk of acute kidney injury in relation to ejection fraction in patients undergoing coronary artery bypass grafting","volume":"274","author":"Hertzberg","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0030","first-page":"807","article-title":"Comparison of perioperative outcomes in heart failure patients with reduced versus preserved ejection fraction after noncardiac surgery","volume":"275","author":"Huang","year":"2022","journal-title":"Ann Surg"},{"key":"2026080802425533100_ejhf70005-bib-0031","article-title":"One size does not fit all: Perioperative management of patients with heart failure with preserved ejection fraction","volume":"94","author":"Gao","year":"2024","journal-title":"J Clin Anesth"},{"key":"2026080802425533100_ejhf70005-bib-0032","first-page":"155","article-title":"Heart failure with preserved ejection fraction: Implications for anaesthesia","volume":"24","author":"Shah","year":"2024","journal-title":"BJA Educ"},{"key":"2026080802425533100_ejhf70005-bib-0033","first-page":"60","article-title":"Diastolic dysfunction, diagnostic and perioperative management in cardiac surgery","volume":"28","author":"Nicoara","year":"2015","journal-title":"Curr Opin Anaesthesiol"},{"key":"2026080802425533100_ejhf70005-bib-0034","article-title":"SGLT-2 inhibitor induced euglycemic diabetes ketoacidosis in post laparoscopic distal pancreatectomy: A case report","volume":"128","author":"Chen","year":"2025","journal-title":"Int J Surg Case Rep"},{"key":"2026080802425533100_ejhf70005-bib-0035","first-page":"2077","article-title":"The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology","volume":"26","author":"Keramida","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0036","first-page":"83","article-title":"Cardiovascular safety in oncology clinical trials: JACC: CardioOncology primer","volume":"7","author":"Bonaca","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026080802425533100_ejhf70005-bib-0037","first-page":"863","article-title":"Atrial disease and heart failure: The common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology","volume":"43","author":"Coats","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0038","first-page":"2214","article-title":"Cancer begets atrial fibrillation \u2026 and vice versa?","volume":"45","author":"Farmakis","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0039","first-page":"321","article-title":"Cancer treatment and atrial fibrillation: Use of pharmacovigilance databases to detect cardiotoxicity","volume":"7","author":"Keramida","year":"2021","journal-title":"Eur Heart J Cardiovas Pharmacother"},{"key":"2026080802425533100_ejhf70005-bib-0040","first-page":"415","article-title":"Cardio-oncology and heart failure: A scientific statement from the Heart Failure Society of America","volume":"31","author":"Bloom","year":"2025","journal-title":"J Card Fail"},{"key":"2026080802425533100_ejhf70005-bib-0041","first-page":"1202","article-title":"A narrative review of heart failure with preserved ejection fraction in breast cancer survivors","volume":"109","author":"Yogeswaran","year":"2023","journal-title":"Heart"},{"key":"2026080802425533100_ejhf70005-bib-0042","first-page":"4649","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080802425533100_ejhf70005-bib-0043","first-page":"1224","article-title":"Heart failure pharmacotherapy and cancer: Pathways and pre-clinical\/clinical evidence","volume":"45","author":"Sayour","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0044","article-title":"Vascular dysfunction in HFpEF: Potential role in the development, maintenance, and progression of the disease","volume":"9","author":"Saavedra-Alvarez","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026080802425533100_ejhf70005-bib-0045","first-page":"62","article-title":"Endothelial glycocalyx integrity in oncological patients","volume":"360","author":"Keramida","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0046","first-page":"367","article-title":"Pulmonary hypertension in heart failure preserved ejection fraction","volume":"7","author":"Guazzi","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0047","first-page":"733","article-title":"Right ventricular function in patients with preserved and reduced ejection fraction heart failure","volume":"10","author":"Puwanant","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"2026080802425533100_ejhf70005-bib-0048","first-page":"71","article-title":"The right heart in heart failure with preserved ejection fraction: Insights from cardiac magnetic resonance imaging and invasive haemodynamics","volume":"18","author":"Aschauer","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0049","article-title":"Cancer therapy-associated pulmonary hypertension and right ventricular dysfunction: Etiologies and prognostic implications","volume":"25","author":"Leiva","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"2026080802425533100_ejhf70005-bib-0050","first-page":"299","article-title":"Cancer therapy-related pulmonary hypertension: A review of mechanisms and implications for clinical practice","volume":"27","author":"G\u00fcrdo\u011fan","year":"2023","journal-title":"Anatol J Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0051","first-page":"835","article-title":"Dasatinib-induced pulmonary arterial hypertension","volume":"84","author":"\u00d6zg\u00fcr Yurtta\u015f","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2026080802425533100_ejhf70005-bib-0052","first-page":"356","article-title":"Chemotherapy-induced pulmonary hypertension: Role of alkylating agents","volume":"185","author":"Ranchoux","year":"2015","journal-title":"Am J Pathol"},{"key":"2026080802425533100_ejhf70005-bib-0053","article-title":"Pulmonary hypertension associated with busulfan","volume":"11","author":"Hagenburg","year":"2021","journal-title":"Pulm Circ"},{"key":"2026080802425533100_ejhf70005-bib-0054","first-page":"32","article-title":"Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist bosentan","volume":"170","author":"Schroll","year":"2010","journal-title":"Respir Physiol Neurobiol"},{"key":"2026080802425533100_ejhf70005-bib-0055","volume-title":"National Cancer Institute. Definition of targeted therapy \u2013 NCI Dictionary of Cancer Terms"},{"key":"2026080802425533100_ejhf70005-bib-0056","volume-title":"National Cancer Institute. List of targeted therapy drugs approved for specific types of cancer"},{"key":"2026080802425533100_ejhf70005-bib-0057","first-page":"3451","article-title":"Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies","volume":"118","author":"Wit","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026080802425533100_ejhf70005-bib-0058","article-title":"Cardiotoxicity due to targeted anticancer agents: A growing challenge","volume":"13","author":"Shah","year":"2019","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2026080802425533100_ejhf70005-bib-0059","first-page":"1310","article-title":"Large artery stiffness and hypertension after antiangiogenic drugs: Influence on cancer progression","volume":"33","author":"Alivon","year":"2015","journal-title":"J Hypertens"},{"key":"2026080802425533100_ejhf70005-bib-0060","article-title":"Possible role of arterial function in cancer treatment targeting vascular endothelial growth factor receptor oncologic response","volume":"33","author":"Vallerio","year":"2015","journal-title":"J Hypertens"},{"key":"2026080802425533100_ejhf70005-bib-0061","first-page":"13","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"2026080802425533100_ejhf70005-bib-0062","first-page":"S89","article-title":"Large artery stiffness in hypertension","volume":"15","author":"Benetos","year":"1997","journal-title":"J Hypertens"},{"key":"2026080802425533100_ejhf70005-bib-0063","first-page":"591","article-title":"Kinase inhibitors and atrial fibrillation: Mechanisms of action and clinical implications","volume":"9","author":"Potter","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"2026080802425533100_ejhf70005-bib-0064","first-page":"27","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026080802425533100_ejhf70005-bib-0065","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: Effects and modifications: A scientific statement from the American Heart Association","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"2026080802425533100_ejhf70005-bib-0066","first-page":"4366","article-title":"Breast cancer and cardiovascular health","volume":"45","author":"L\u00f3pez-Fern\u00e1ndez","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0067","first-page":"360","article-title":"Cardiovascular manifestations from therapeutic radiation: A multidisciplinary expert consensus statement from the International Cardio-Oncology Society","volume":"3","author":"Mitchell","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026080802425533100_ejhf70005-bib-0068","first-page":"880","article-title":"Consequences of ionizing radiation exposure to the cardiovascular system","volume":"21","author":"Jahng","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0069","first-page":"H392","article-title":"Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction","volume":"313","author":"Saiki","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026080802425533100_ejhf70005-bib-0070","first-page":"836","article-title":"Cardiovascular complications after radiotherapy","volume":"27","author":"Nabia\u0142ek-Trojanowska","year":"2020","journal-title":"Cardiol J"},{"key":"2026080802425533100_ejhf70005-bib-0071","first-page":"124","article-title":"Radiotherapy-induced diffuse myocardial fibrosis in early-stage breast cancer patients \u2013 multimodality imaging study with six-year follow-up","volume":"18","author":"Moisander","year":"2023","journal-title":"Radiation Oncol"},{"key":"2026080802425533100_ejhf70005-bib-0072","first-page":"1059","article-title":"Stiff left atrial syndrome after low-dose radiotherapy for right breast cancer: The need for invasive hemodynamics at exercise","volume":"95","author":"Baratto","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026080802425533100_ejhf70005-bib-0073","first-page":"H1267","article-title":"Mapping genetic modifiers of radiation-induced cardiotoxicity to rat chromosome 3","volume":"316","author":"Schlaak","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026080802425533100_ejhf70005-bib-0074","first-page":"1451","article-title":"From systemic inflammation to myocardial fibrosis: The heart failure with preserved ejection fraction paradigm revisited","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ Res"},{"key":"2026080802425533100_ejhf70005-bib-0075","first-page":"2488","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080802425533100_ejhf70005-bib-0076","first-page":"637","article-title":"Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer","volume":"559","author":"Wu","year":"2018","journal-title":"Nature"},{"key":"2026080802425533100_ejhf70005-bib-0077","first-page":"1165","article-title":"Clonal hematopoiesis in clinical and experimental heart failure with preserved ejection fraction","volume":"148","author":"Cochran","year":"2023","journal-title":"Circulation"},{"key":"2026080802425533100_ejhf70005-bib-0078","article-title":"Clonal hematopoiesis and incident heart failure with preserved ejection fraction","volume":"7","author":"Schuermans","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026080802425533100_ejhf70005-bib-0079","first-page":"4","article-title":"Clonal haematopoiesis of indeterminate potential: Associations with heart failure incidence, clinical parameters and biomarkers","volume":"25","author":"Shi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0080","first-page":"791","article-title":"Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias","volume":"45","author":"Schuermans","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0081","first-page":"497","article-title":"Atrial fibrillation and clonal hematopoiesis in TET2 and ASXL1","volume":"9","author":"Saadatagah","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0082","first-page":"263","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0083","first-page":"2055","article-title":"Cardiovascular toxicities of immune therapies for cancer \u2013 a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0084","first-page":"21","article-title":"The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: Including myocarditis and the new entity of non inflammatory left ventricular dysfunction","volume":"8","author":"Andres","year":"2022","journal-title":"Cardiooncology"},{"key":"2026080802425533100_ejhf70005-bib-0085","first-page":"879","article-title":"High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction","volume":"111","author":"Tsch\u00f6pe","year":"2005","journal-title":"Circulation"},{"key":"2026080802425533100_ejhf70005-bib-0086","first-page":"808","article-title":"Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF","volume":"146","author":"Selvaraj","year":"2022","journal-title":"Circulation"},{"key":"2026080802425533100_ejhf70005-bib-0087","first-page":"1474","article-title":"Cardiovascular effects of oral ketone ester treatment in patients with heart failure with reduced ejection fraction: A randomized, controlled, double-blind trial","volume":"149","author":"Berg-Hansen","year":"2024","journal-title":"Circulation"},{"key":"2026080802425533100_ejhf70005-bib-0088","first-page":"999","article-title":"Targeted metabolomic profiling of dapagliflozin in heart failure with preserved ejection fraction: The PRESERVED-HF trial","volume":"12","author":"Selvaraj","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0089","first-page":"1570","article-title":"Randomized crossover trial of 2-week ketone ester treatment in patients with type 2 diabetes and heart failure with preserved ejection fraction","volume":"150","author":"Gopalasingam","year":"2024","journal-title":"Circulation"},{"key":"2026080802425533100_ejhf70005-bib-0090","first-page":"798","article-title":"The cardiotoxic effects of CAR-T cell therapy: An updated systematic review and meta-analysis","volume":"113","author":"Mazetto","year":"2024","journal-title":"Eur J Haematol"},{"key":"2026080802425533100_ejhf70005-bib-0091","article-title":"Impaired T cell IRE1\u03b1\/XBP1 signaling directs inflammation in experimental heart failure with preserved ejection fraction","volume":"133","author":"Smolgovsky","year":"2023","journal-title":"J Clin Invest"},{"key":"2026080802425533100_ejhf70005-bib-0092","first-page":"351","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"2026080802425533100_ejhf70005-bib-0093","first-page":"679","article-title":"Unfolding discoveries in heart failure","volume":"382","author":"Paulus","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080802425533100_ejhf70005-bib-0094","first-page":"1663","article-title":"The emerging field of cardioimmunology: Past, present and foreseeable future","volume":"134","author":"Mann","year":"2024","journal-title":"Circ Res"},{"key":"2026080802425533100_ejhf70005-bib-0095","first-page":"430","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"2026080802425533100_ejhf70005-bib-0096","article-title":"HBI-8000 improves heart failure with preserved ejection fraction via the TGF-\u03b21\/MAPK signalling pathway","volume":"28","author":"Tian","year":"2024","journal-title":"J Cell Mol Med"},{"key":"2026080802425533100_ejhf70005-bib-0097","article-title":"Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: Diagnostic challenges and lessons learned","volume":"9","author":"Borgers","year":"2024","journal-title":"ESMO Open"},{"key":"2026080802425533100_ejhf70005-bib-0098","first-page":"116","article-title":"Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers","volume":"4","author":"Karthikeyan","year":"2024","journal-title":"Commun Med"},{"key":"2026080802425533100_ejhf70005-bib-0099","first-page":"1070","article-title":"Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lung","volume":"10","author":"Kazemi-Bajestani","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026080802425533100_ejhf70005-bib-0100","first-page":"1569","article-title":"Clinical and prognostic relevance of cardiac wasting in patients with advanced cancer","volume":"81","author":"Lena","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0101","first-page":"3135","article-title":"Cardiac wasting and cancer","volume":"45","author":"Anker","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0102","first-page":"347","article-title":"Cardiac alterations in cancer-induced cachexia in mice","volume":"37","author":"Tian","year":"2010","journal-title":"Int J Oncol"},{"key":"2026080802425533100_ejhf70005-bib-0103","first-page":"140","article-title":"Advanced cancer is also a heart failure syndrome: A hypothesis","volume":"23","author":"Anker","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0104","first-page":"638","article-title":"Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: A target trial emulation using the SEER-Medicare database","volume":"57","author":"Truong","year":"2024","journal-title":"J Thromb Thrombolysis"},{"key":"2026080802425533100_ejhf70005-bib-0105","first-page":"171","article-title":"SGLT2i therapy prevents anthracycline-induced cardiotoxicity in a large animal model by preserving myocardial energetics","volume":"7","author":"Medina-Hern\u00e1ndez","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026080802425533100_ejhf70005-bib-0106","first-page":"352","article-title":"Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0107","article-title":"Dyspnea in oncological patients: A brain teaser","volume":"18","author":"Keramida","year":"2023","journal-title":"Eur Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0108","first-page":"861","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"2026080802425533100_ejhf70005-bib-0109","first-page":"3297","article-title":"How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0110","first-page":"1941","article-title":"Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality","volume":"43","author":"Verbrugge","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0111","first-page":"1835","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0112","article-title":"Plasma brain natriuretic peptide levels are elevated in patients with cancer","volume":"12","author":"Bando","year":"2017","journal-title":"PLoS One"},{"key":"2026080802425533100_ejhf70005-bib-0113","first-page":"155","article-title":"Human small cell lung cancer cells produce brain natriuretic peptide","volume":"56","author":"Ohsaki","year":"1999","journal-title":"Oncology"},{"key":"2026080802425533100_ejhf70005-bib-0114","first-page":"352","article-title":"Immunoreactive brain natriuretic peptide in human adrenal glands and adrenal tumors","volume":"135","author":"Totsune","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"2026080802425533100_ejhf70005-bib-0115","first-page":"341","article-title":"High N-terminal pro-B-type natriuretic peptide: A biomarker of lung cancer?","volume":"11","author":"Aujollet","year":"2010","journal-title":"Clin Lung Cancer"},{"key":"2026080802425533100_ejhf70005-bib-0116","first-page":"100","article-title":"Role of global longitudinal strain in assessment of left ventricular systolic function in patients with heart failure with preserved ejection fraction","volume":"31","author":"Bshiebish","year":"2019","journal-title":"J Saudi Heart Assoc"},{"key":"2026080802425533100_ejhf70005-bib-0117","first-page":"893","article-title":"Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: Insights from the RELAX trial","volume":"19","author":"DeVore","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0118","first-page":"1490","article-title":"Left atrial strain in evaluation of heart failure with preserved ejection fraction","volume":"33","author":"Ye","year":"2020","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080802425533100_ejhf70005-bib-0119","first-page":"891","article-title":"Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction","volume":"21","author":"Reddy","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0120","first-page":"61","article-title":"Determinants of left atrial reservoir and pump strain and use of atrial strain for evaluation of left ventricular filling pressure","volume":"23","author":"Inoue","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080802425533100_ejhf70005-bib-0121","first-page":"e34","article-title":"Multimodality imaging in patients with heart failure and preserved ejection fraction: An expert consensus document of the European Association of Cardiovascular Imaging","volume":"23","author":"Smiseth","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080802425533100_ejhf70005-bib-0122","first-page":"169","article-title":"The impact of patients with cardiac amyloidosis in HFpEF trials","volume":"9","author":"Oghina","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0123","first-page":"12","article-title":"Management of heart failure with preserved ejection fraction","volume":"43","author":"Gard","year":"2020","journal-title":"Aust Prescr"},{"key":"2026080802425533100_ejhf70005-bib-0124","first-page":"415","article-title":"Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy","volume":"101","author":"Lange","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0125","article-title":"Valvular heart disease following anthracycline therapy \u2013 is it time to look beyond ejection fraction?","volume":"12","author":"Zahler","year":"2022","journal-title":"Life (Basel)"},{"key":"2026080802425533100_ejhf70005-bib-0126","first-page":"412","article-title":"Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation","volume":"117","author":"Galper","year":"2011","journal-title":"Blood"},{"key":"2026080802425533100_ejhf70005-bib-0127","first-page":"2831","article-title":"Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy","volume":"290","author":"Hull","year":"2003","journal-title":"JAMA"},{"key":"2026080802425533100_ejhf70005-bib-0128","first-page":"1878","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"2026080802425533100_ejhf70005-bib-0129","first-page":"230","article-title":"Valvular dysfunction in lymphoma survivors treated with autologous stem cell transplantation: A national cross-sectional study","volume":"9","author":"Murbraech","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080802425533100_ejhf70005-bib-0130","first-page":"269","article-title":"Radiation-induced valvular heart disease","volume":"102","author":"Gujral","year":"2016","journal-title":"Heart"},{"key":"2026080802425533100_ejhf70005-bib-0131","first-page":"2288","article-title":"Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions","volume":"148","author":"\u00c7elik","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026080802425533100_ejhf70005-bib-0132","first-page":"479","article-title":"A structured, parsimonious approach to establish the cause of moderate-to-large pericardial effusion","volume":"114","author":"Agarwal","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0133","first-page":"1119","article-title":"Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion","volume":"66","author":"El Haddad","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0134","first-page":"412","article-title":"Pericardiocentesis versus pericardiotomy for malignant pericardial effusion: A retrospective comparison","volume":"22","author":"Labb\u00e9","year":"2015","journal-title":"Curr Oncol"},{"key":"2026080802425533100_ejhf70005-bib-0135","article-title":"Reported pericardial toxicities associated with acute myelogenous leukemia treatments: A pharmacovigilance analysis of the FDA adverse reporting database","volume":"47","author":"Janus","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0136","first-page":"853","article-title":"Acute pleural and pericardial effusion induced by chemotherapy in treating chronic myelocytic leukemia","volume":"60","author":"He","year":"2014","journal-title":"Clin Lab"},{"key":"2026080802425533100_ejhf70005-bib-0137","first-page":"713","article-title":"Pleural\/pericardic effusions during dasatinib treatment: Incidence, management and risk factors associated to their development","volume":"9","author":"Breccia","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"2026080802425533100_ejhf70005-bib-0138","article-title":"Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): A retrospective pharmacovigilance study","volume":"13","author":"Huang","year":"2023","journal-title":"BMJ Open"},{"key":"2026080802425533100_ejhf70005-bib-0139","first-page":"79","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"2026080802425533100_ejhf70005-bib-0140","first-page":"6","article-title":"Managing cardiotoxicity associated with immune checkpoint inhibitors","volume":"5","author":"Upadhrasta","year":"2019","journal-title":"Chronic Dis Transl Med"},{"key":"2026080802425533100_ejhf70005-bib-0141","first-page":"70","article-title":"Incidence and predictors of pericardial effusion after chemoradiation therapy for locally advanced non-small cell lung cancer","volume":"99","author":"Ning","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080802425533100_ejhf70005-bib-0142","first-page":"343","article-title":"Past, present, and future of radiation-induced cardiotoxicity: Refinements in targeting, surveillance, and risk stratification","volume":"3","author":"Bergom","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026080802425533100_ejhf70005-bib-0143","first-page":"804","article-title":"Renal cell carcinoma presenting with cardiac failure","volume":"61","author":"Piggott","year":"2000","journal-title":"Hosp Med"},{"key":"2026080802425533100_ejhf70005-bib-0144","first-page":"901","article-title":"A case of arteriovenous fistulae secondary to renal cell carcinoma accompanied by congestive heart failure","volume":"29","author":"Nakada","year":"1983","journal-title":"Hinyokika Kiyo"},{"key":"2026080802425533100_ejhf70005-bib-0145","first-page":"345","article-title":"Arteriovenous fistulae secondary to renal cell carcinoma. Clinical and cardiovascular manifestations: Report of a case","volume":"52","author":"Rodgers","year":"1975","journal-title":"Circulation"},{"key":"2026080802425533100_ejhf70005-bib-0146","first-page":"22","article-title":"Digging deep: High output heart failure in renal cell carcinoma","volume":"127","author":"Hayek","year":"2014","journal-title":"Am J Med"},{"key":"2026080802425533100_ejhf70005-bib-0147","first-page":"2979","article-title":"High-output heart failure caused by a tumor-related arteriovenous fistula: A case report and literature review","volume":"60","author":"Tobe","year":"2021","journal-title":"Intern Med"},{"key":"2026080802425533100_ejhf70005-bib-0148","article-title":"High-output heart failure associated with primary plasma cell leukaemia due to arteriovenous shunting: A case report","volume":"5","author":"Sudo","year":"2021","journal-title":"Eur Heart J Case Rep"},{"key":"2026080802425533100_ejhf70005-bib-0149","first-page":"235","article-title":"High output heart failure","volume":"102","author":"Mehta","year":"2009","journal-title":"QJM"},{"key":"2026080802425533100_ejhf70005-bib-0150","first-page":"3627","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0150","first-page":"53","volume":"45","year":"2024","journal-title":"Eur Heart J."},{"key":"2026080802425533100_ejhf70005-bib-0151","first-page":"1475","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080802425533100_ejhf70005-bib-0152","first-page":"1069","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080802425533100_ejhf70005-bib-0153","first-page":"1394","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080802425533100_ejhf70005-bib-0154","first-page":"427","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080802425533100_ejhf70005-bib-0155","first-page":"321","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0156","article-title":"IL-1 blockade in patients with heart failure with preserved ejection fraction","volume":"11","author":"Van Tassell","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0157","article-title":"Differential response to interleukin-1 blockade with anakinra on cardiorespiratory fitness in patients with heart failure with preserved ejection fraction stratified according to left ventricular ejection fraction","volume":"12","author":"Golino","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026080802425533100_ejhf70005-bib-0158","first-page":"1289","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"2026080802425533100_ejhf70005-bib-0159","first-page":"933","article-title":"Inflammation and cardio-renal interactions in heart failure: A potential role for interleukin-6","volume":"20","author":"Hanberg","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0160","first-page":"104","article-title":"Myeloperoxidase inhibition in heart failure with preserved or mildly reduced ejection fraction: SATELLITE trial results","volume":"30","author":"Lam","year":"2024","journal-title":"J Card Fail"},{"key":"2026080802425533100_ejhf70005-bib-0161","first-page":"1696","article-title":"Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction","volume":"25","author":"Lund","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0162","first-page":"892","article-title":"Verinurad plus allopurinol for heart failure with preserved ejection fraction: The AMETHYST randomized clinical trial","volume":"9","author":"Kitzman","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026080802425533100_ejhf70005-bib-0163","first-page":"190","article-title":"Tailoring medical therapy for heart failure with preserved ejection fraction","volume":"27","author":"Inciardi","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026080802425533100_ejhf70005-bib-0164","volume-title":"FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract nfections. FDA Drug Safety Communication","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"2026080802425533100_ejhf70005-bib-0165","first-page":"2530","article-title":"Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum","volume":"30","author":"Jones","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026080802425533100_ejhf70005-bib-0166","first-page":"2267","article-title":"Exercise capacity is reduced in cancer survivors previously treated with anthracycline-based chemotherapy despite a preserved cardiac output response","volume":"12","author":"Brubaker","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080802425533100_ejhf70005-bib-0167","article-title":"Increased skeletal intermuscular fat is associated with reduced exercise capacity in cancer survivors: A cross-sectional study","volume":"5","author":"Reding","year":"2019","journal-title":"Cardiooncology"},{"key":"2026080802425533100_ejhf70005-bib-0168","first-page":"4825","article-title":"Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer","volume":"116","author":"Jones","year":"2010","journal-title":"Cancer"},{"key":"2026080802425533100_ejhf70005-bib-0169","first-page":"444","article-title":"Impact of cancer history on temporal changes in the cardiopulmonary exercise test of patients with cardiovascular disease","volume":"65","author":"Satogami","year":"2024","journal-title":"Int Heart J"},{"key":"2026080802425533100_ejhf70005-bib-0170","first-page":"272","article-title":"Cardiorespiratory fitness as predictor of cancer mortality: A systematic review and meta-analysis","volume":"26","author":"Schmid","year":"2015","journal-title":"Ann Oncol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2152\/66833525\/eurjhf_27_11_2152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2152\/66833525\/eurjhf_27_11_2152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T06:43:01Z","timestamp":1786171381000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/11\/2152\/8470227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":171,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,9,12]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.70005","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"2025-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}